Silverback Therapeutics Inc. (SBTX) News

Silverback Therapeutics Inc. (SBTX): $3.15

0.03 (+0.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SBTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Filter SBTX News Items

SBTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SBTX News Highlights

  • For SBTX, its 30 day story count is now at 3.
  • Over the past 21 days, the trend for SBTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about SBTX are PEAR.

Latest SBTX News From Around the Web

Below are the latest news stories about Silverback Therapeutics Inc that investors may wish to consider to help them evaluate SBTX as an investment opportunity.

Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

SEATTLE, February 24, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.

Yahoo | February 24, 2022

Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SEATTLE, February 03, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022.

Yahoo | February 3, 2022

5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ...

Investment company 5AM Venture Management, LLC (Current Portfolio) buys Pear Therapeutics Inc, Entrada Therapeutics Inc, sells Crinetics Pharmaceuticals Inc, Avidity Biosciences Inc, Silverback Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, 5AM Venture Management, LLC.

Yahoo | February 3, 2022

Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference

SEATTLE, January 05, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.

Yahoo | January 5, 2022

Deadline Tuesday Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

DEADLINE TUESDAY NOTICE : The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encou

Yahoo | January 1, 2022

Silverback Shareholder Notice

Silverback Shareholder Notice

Yahoo | December 31, 2021

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Silverback Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Silverback Therapeutics, Inc. ("Silverback" or "the Company") (NASDAQ: SBTX) for violations of the federal securities laws.

Yahoo | December 31, 2021

DEADLINE TUESDAY ALERT: The Schall Law Firm Encourages Investors in Silverback Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 31, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Silverback Therapeutics, Inc. ("Silverback" or "the Company") (NASDAQ:SBTX) for violations of the federal securities laws.

Yahoo | December 31, 2021

Deadline Tuesday Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Deadline Tuesday Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Silverback Therapeutics, Inc. and Encoura

Yahoo | December 30, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Silverback Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2022 – SBTX

NEW YORK, NY / ACCESSWIRE / December 30, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:To: All persons and entities that purchased or otherwise acquired: (a) Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ:SBTX) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about December 3, 2020; and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, bo

Yahoo | December 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4676 seconds.